.gif)
Alvogen, the next generation pharmaceuticals company, has launched the first generic equivalent to Tamiflu (oseltamivir phosphate) capsules in the United States.
Alvogen expects the generic equivalent to Tamiflu capsules to deliver significant savings for patients and health providers of up to $500 million during this upcoming season. The product is available in three strengths (30 mg, 45 mg and 75 mg).
Robert Wessman, chairman and CEO of Alvogen, commented: “The launch of oseltamivir phosphate is great news for US patients, who will finally have access to a more affordable alternative to Tamiflu. It is also an important milestone for our US business. The launch demonstrates our ability to move quickly and we are proud to partner with Natco to bring this product to market.”
Alvogen currently has 79 products in development and pending FDA approval for the US market. Annual brand sales for filed products and those under development have current brand sales exceeding $25 billion, according to IMS Health (2015).
